Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer

Bhatt, Aditi; Goèré, Diane

doi:10.1007/s13193-016-0499-z

Cited by 23 publications

(9 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nowadays, these patients can benefit from treatment by multidisciplinary units that allow the combination of surgical cytoreduction and HIPEC with systemic chemotherapy. This type of management offers the best survival rate and is the treatment of choice in selected patients (2…”

Section: Dear Editormentioning

confidence: 99%

From utopia to reality: increased survival in peritoneal carcinomatosis treated with cytoreduction and hyperthermic intraperitoneal chemotherapy

Segura-Sampedro

Morales-Soriano

2017

Rev Esp Enferm Dig

View full text Add to dashboard Cite

We have read with great interest the article by Illán et al.1 entitled "Long survival in a patient with metastatic colorectal carcinoma: reality or utopia?" This article describes the case of a 42 year old patient with mucinous-type colon adenocarcinoma who had tumor recurrence with peritoneal metastases 18 months after resection of the primary tumor and adjuvant chemotherapy. After multiple metastasectomies and several lines of chemotherapy, the patient died 27 months after the recurrence.

show abstract

Section: Dear Editormentioning

confidence: 99%

From utopia to reality: increased survival in peritoneal carcinomatosis treated with cytoreduction and hyperthermic intraperitoneal chemotherapy

Segura-Sampedro

Morales-Soriano

2017

Rev Esp Enferm Dig

View full text Add to dashboard Cite

show abstract

“…15 In addition, clinical trials are also a treatment selection for each stage. This test also allows for the removal of polyps.…”

Section: Stages Of Crcmentioning

confidence: 99%

Recent insights into nanotechnology development for detection and treatment of colorectal cancer

Viswanath¹,

Kim²,

Lee³

2016

IJN

View full text Add to dashboard Cite

The global incidence of colorectal cancer (CRC) is 1.3 million cases. It is the third most frequent cancer in males and females. Most CRCs are adenocarcinomas and often begin as a polyp on the inner wall of the rectum or colon. Some of these polyps become malignant, eventually. Detecting and removing these polyps in time can prevent CRC. Therefore, early diagnosis of CRC is advantageous for preventive and instant action interventions to decrease the mortality rates. Nanotechnology has been enhancing different methods for the detection and treatment of CRCs, and the research has provided hope within the scientific community for the development of new therapeutic strategies. This review presents the recent development of nanotechnology for the detection and treatment of CRC.

show abstract

“…Metachronous PM reportedly occurs in 4–19% of these patients . In 15–20% of patients, it manifests as the only site of metastasis after primary CRC resection . The tendency for peritoneal recurrence may be related to intraperitoneal seeding .…”

Section: Introductionmentioning

confidence: 99%

“…[1][2][3] In 15-20% of patients, it manifests as the only site of metastasis after primary CRC resection. 4 The tendency for peritoneal recurrence may be related to intraperitoneal seeding. 5 The conventional approach of CRPM included systemic chemotherapy (5-fluorouracil (5-FU) and leucovorin) with or without palliative surgery, 6 resulting in poor survival outcome of approximately 6 months.…”

Section: Introductionmentioning

confidence: 99%

Prevention of peritoneal recurrence in high‐risk colorectal cancer and evidence of T4 status as a potential risk factor

Kyang

Valle

Alzahrani

et al. 2018

ANZ Journal of Surgery

View full text Add to dashboard Cite

Peritoneal metastasis (PM) following primary resection of colorectal cancer is common. The combined use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy has significantly improved the survival outcome of patients with colorectal PM (CRPM). Diagnosing and treating early PM is essential as its extent is correlated with poorer outcomes. There are two novel therapies - second-look surgery and synchronous hyperthermic intraperitoneal chemotherapy - that are proposed to prophylactically treat or intervene early in the disease process to reduce the incidence and adverse outcomes associated with PM. These strategies are limited to patients at high risk of developing CRPM, including those that had synchronous PM or ovarian metastases resected at primary tumour removal, or a perforated primary tumour. The data on advanced primary tumour (T4) as a prognostic factor for PM after primary resection suggest that T4a tumours are prognostically worse than T4b. This literature review outlines the evidence, feasibility and safety regarding the pre-emptive treatments, as well as the relevance of T4a tumours as a risk factor for metachronous CRPM.

show abstract

Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer

Cited by 23 publications

References 76 publications

From utopia to reality: increased survival in peritoneal carcinomatosis treated with cytoreduction and hyperthermic intraperitoneal chemotherapy

From utopia to reality: increased survival in peritoneal carcinomatosis treated with cytoreduction and hyperthermic intraperitoneal chemotherapy

Recent insights into nanotechnology development for detection and treatment of colorectal cancer

Prevention of peritoneal recurrence in high‐risk colorectal cancer and evidence of T4 status as a potential risk factor

Contact Info

Product

Resources

About